# US 11,305,023 B2 · Method for diagnostically imaging lesions in the peripheral nervous system > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,305,023 B2 - Document ID: US11305023B2 - Status: Granted - Kind: B2 - Application number: 13/675,306 - Filed: 2012-11-13 - Published: 2013-05-16 - Granted: 2022-04-19 - Earliest claimed: 2011-11-11 - Applicants: Sam Popinchalk - Inventors: Sam Popinchalk - Web page: https://patentgrep.com/patent/US11305023B2 ## CPC - A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents} - A61K 49/16: Antibodies; Immunoglobulins; Fragments thereof - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention. ## Claims ### Claim 1 A method to characterize peripheral nerve lesions by detecting blood-nerve barrier permeability, the method including the steps of: introducing a chemical agent to a peripheral nerve having a blood-nerve barrier to characterize peripheral nerve lesions, the chemical agent operable to interact with an epitope within the blood-nerve barrier, detecting blood-nerve barrier permeability by analyzing the peripheral nerve to detect an amount of the chemical agent at a site of the blood-nerve barrier permeability, the blood-nerve barrier permeability caused by a lesion, wherein, the chemical agent (i) does not interact with the epitope unless the blood-nerve barrier is permeable and allows the epitope to be exposed to the chemical agent, and (ii) is operable to localize at the site of the blood-nerve barrier permeability, and the method does not include modification of the blood-nerve barrier permeability. ### Claim 2 (depends on 1) The method of claim 1, further comprising the step of: attaching a label to the chemical agent, wherein, the chemical agent is operable to localize in regions where the blood-nerve barrier is disrupted. ### Claim 3 (depends on 2) The method of claim 2, wherein the analyzing of the peripheral nerve includes determining the amount of the chemical agent present in the peripheral nerve. ### Claim 4 (depends on 3) The method of claim 3, wherein, the analyzing of the peripheral nerve is performed using magnetic resonance imaging, and the label has a magnetic resonance imaging contrast agent. ### Claim 5 (depends on 1) The method of claim 1, wherein the chemical agent is a monoclonal antibody. ### Claim 6 (depends on 1) The method of claim 1, wherein the chemical agent is operable to bind exclusively to the peripheral nerve lesions. ### Claim 7 (depends on 1) The method of claim 1, wherein the chemical agent is an antibody against an axonal protein. ### Claim 8 (depends on 1) The method of claim 1, wherein the blood-nerve barrier is permeable due to neurotmesis. ### Claim 9 A method to diagnose a nerve injury using a chemical agent having a label by detecting permeability of a blood-nerve barrier of a peripheral nerve, the method including the steps of: introducing the chemical agent having the label to the blood-nerve barrier, the chemical agent operable to bind to an epitope exposed at a permeable site of the blood-nerve barrier; and detecting blood-nerve barrier permeability by imaging the peripheral nerve using magnetic resonance imaging to determine a presence of the chemical agent at the permeable site of the blood-nerve barrier, the blood-nerve barrier permeability caused by an injury, wherein, the label is (i) attached to the chemical agent, (ii) a contrast agent, and (iii) operable to localize and be detected at peripheral nerve injury sites that demonstrate blood-nerve barrier permeability via the magnetic resonance imaging. ### Claim 10 (depends on 1) The method of claim 1, wherein the method enables accurate analysis of the peripheral nerve lesions and the ability to distinguish axonotmetic lesions with greater self-regeneration potential from neurotmetic lesions that may require intervention. ### Claim 11 (depends on 9) The method of claim 9, wherein, the permeable site of the blood-nerve barrier is a disruption in the blood-nerve barrier, and the chemical agent is operable to localize in regions where the blood-nerve barrier is disrupted. ### Claim 12 (depends on 1) The method of claim 1, wherein, the lesion features (i) a loss of axons, and (ii) disruption of endoneurium and perineurium. ### Claim 13 (depends on 1) The method of claim 1, wherein, the lesion is a neurotmetic lesion or related to birth palsy. ### Claim 14 (depends on 9) The method of claim 9, wherein, the permeable site of the blood-nerve barrier is caused by a lesion. ### Claim 15 (depends on 14) The method of claim 14, wherein, the lesion features (i) a loss of axons, and (ii) disruption of endoneurium and perineurium. ### Claim 16 (depends on 14) The method of claim 14, wherein, the injury is a neurotmetic injury or related to birth palsy. ### Claim 17 (depends on 9) The method of claim 9, wherein, the method does not include modification of permeability of the blood-nerve barrier. ### Claim 18 (depends on 9) The method of claim 9, wherein, the method enables accurate analysis of peripheral nerve lesions and ability to distinguish axonotmetic lesions with greater self-regeneration potential from neurotmetic lesions that may require intervention. ### Claim 19 (depends on 9) The method of claim 9, wherein, the label is gadolinium-DTPA or superparamagnetic iron oxide nanoparticles. ### Claim 20 In a peripheral nerve having connective tissue layers comprising a blood-nerve barrier that normally protects an epitope within the blood-nerve barrier from interaction with a chemical agent outside the blood-nerve barrier, a method for distinguishing peripheral nerve lesions in which the blood-nerve barrier remains intact from other peripheral nerve lesions in which the blood-nerve barrier has been disrupted to become permeable, the method comprising the steps of: providing a quantity of the chemical agent that normally does not cross an intact blood-nerve barrier of the peripheral nerve, the chemical agent operable to interact with the epitope within the blood-nerve barrier if the blood-nerve barrier has been disrupted to become permeable thereby permitting the chemical to cross the blood-nerve barrier, the chemical agent operable to localize at a site where the blood-nerve barrier has become permeable; introducing the chemical agent to the blood-nerve barrier; allowing the chemical agent to cross the blood-nerve barrier at a peripheral nerve site where the blood-nerve barrier has become permeable and allowing the chemical agent to bind with the epitope at the peripheral nerve site; and detecting an amount of the chemical agent at the peripheral nerve site to characterize severity of a peripheral nerve lesion.